Biodexa Pharmaceuticals Plc ADR [NASDAQ: BDRX] gained 16.13% or 0.32 points to close at $2.34 with a heavy trading volume of 38116697 shares.
The daily chart for BDRX points out that the company has recorded -76.61% loss over the past six months.
If we look at the average trading volume of 914.37K shares, BDRX reached to a volume of 38116697 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Biodexa Pharmaceuticals Plc ADR [BDRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BDRX shares is $18.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BDRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Biodexa Pharmaceuticals Plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 08, 2024.
The Average True Range (ATR) for Biodexa Pharmaceuticals Plc ADR is set at 0.50, with the Price to Sales ratio for BDRX stock in the period of the last 12 months amounting to 13.57. The Price to Book ratio for the last quarter was 0.18, with the Price to Cash per share for the same quarter was set at 11.02.
Trading performance analysis for BDRX stock
Biodexa Pharmaceuticals Plc ADR [BDRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.39. With this latest performance, BDRX shares dropped by -45.83% in over the last four-week period, additionally sinking by -76.61% over the last 6 months – not to mention a drop of -92.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BDRX stock in for the last two-week period is set at 36.56, with the RSI for the last a single of trading hit 39.29, and the three-weeks RSI is set at 36.83 for Biodexa Pharmaceuticals Plc ADR [BDRX]. The present Moving Average for the last 50 days of trading for this stock 3.78, while it was recorded at 2.07 for the last single week of trading, and 9.97 for the last 200 days.
Biodexa Pharmaceuticals Plc ADR [BDRX]: A deeper dive into fundamental analysis
Biodexa Pharmaceuticals Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.16 and a Current Ratio set at 2.16.
Biodexa Pharmaceuticals Plc ADR [BDRX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BDRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biodexa Pharmaceuticals Plc ADR go to 89.98%.
An analysis of Institutional ownership at Biodexa Pharmaceuticals Plc ADR [BDRX]
There are presently around $29.86%, or 32.75%% of BDRX stock, in the hands of institutional investors.
